InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life.
OUR ADVANTAGES
Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results.
EXPECTED EARLY REVENUES:
InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added “excipients” to existing approved OTC drugs.
TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS
InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance.
FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGN
The companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health.
To join the investment opportunity with InnoCan, please contact Iris Bincovich at
IrisB@InnocanPharma.com.
OUR ADVANTAGES
Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results.
EXPECTED EARLY REVENUES:
InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added “excipients” to existing approved OTC drugs.
TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS
InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance.
FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGN
The companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health.
To join the investment opportunity with InnoCan, please contact Iris Bincovich at
IrisB@InnocanPharma.com.
Location: Israel, Tel Aviv District, Herzliya
Employees: 11-50
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Invicta Ve... | invicta.vc |
Mentions in press and media 11
| Date | Title | Description |
| 12.03.2023 | Innocan Pharma Announces First Patent Grant in the United States | This is the first fully granted patent of Innocan in the United States The Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolio Herzliya, Is... |
| 03.09.2021 | Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has conducted a ... |
| 28.07.2021 | Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") filed a patent application for its topical compositi... |
| 09.07.2021 | Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") announces the filing of an international patent appli... |
| 14.06.2021 | INNOCAN PHARMA CORPORATION Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is honored to announce it has filed an international... |
| 14.05.2021 | INNOCAN PHARMA CORPORATION Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today that a recent study con... |
| 06.05.2021 | INNOCAN PHARMA CORPORATION Innocan Pharma Announces Trading on the OTCQB Venture Market and DTC Eligibility of Its Common Shares in the United States | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 6, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it is currently trading on... |
| 01.04.2021 | INNOCAN PHARMA CORPORATION Innocan Reports Q4 2020 Financial Results | Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 1, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today its financial results ... |
| 10.06.2020 | INNOCAN PHARMA CORPORATION Innocan Pharma Announces Closing of $5.1 Million Prospectus Offering of Units | Toronto, Ontario--(Newsfile Corp. - June 10, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce the closing of its marketed short form prospectus offering pursu... |
| 02.06.2020 | INNOCAN PHARMA CORPORATION Innocan Pharma Amends Terms of Marketed Short Form Prospectus Offering of Units | Toronto, Ontario--(Newsfile Corp. - June 2, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that it has amended certain terms of its marketed offering of units of the Com... |
Show more